Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rosetta Genomics, Ltd. (the “Company”) received a staff deficiency letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the past 30 consecutive business days, the closing bid price per share of its ordinary shares was below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As a result, the Company was notified by Nasdaq that it is not in compliance with the Bid Price Rule. Nasdaq has provided the Company with 180 calendar days, or until April 11, 2017, to regain compliance with the Bid Price Rule.
Is this dead now no love I guess people hate ceo that dilute to the max
Stock once worth over $3000.00 a share, now sold for 60 cents...
Company has 45 days from October 24th to file their plan for regaining compliance for NASDAQ. So we should see some news coming that outlines their financials and their way ahead. $ROSG
In the meantime the only play here is to short it. Otherwise garbage.
I hope you bought yesterday.... Greets, D
And did a 1/12 rs in March.
It has not had any bounces?
Don't know. It keeps going down. I'm following ROSG for over 5years now and it never gave any stockholders value. The product is good, if it ver make it to the market.
How do you see ROSG now? Seems like a good entry point right? Many biotechs bounce from this level
Wow... back under 1$... i might get in here.
Trying to figure out why this is still down. Price should be 1.50 to 2.00 easy!
ROSG
Rosetta nabs U.S. patent covering microRNA in gastric cancer; shares ahead 12%
http://www.seekingalpha.com/news/3296398
Wow. Insane volume today. Something is up for sure. Buying as much as i can. Long!
ROSG Approaching HOD on huge volume. May blow top!
ROSG Looking super strong. Will explode when news hits wire.
And back below $2.00. Give it a year and yet another R/S will take it to a .02 worth. What's that 5 R/S's now?
Wash, rinse, repeat
Yup! Read it, Surprise!, more losses, more dumping. This company will continue this way for another 4 years at least. Dump shares to pay for themselves, then do another reverse.
Over, and over, and over"..............
Earnings out and conference call today at 10:00 eastern!
Not to worry, they will do the same over and over. In a year this will be diluted and ready for another reverse. Bet the ink isn't even dry on this reverse before an announcement of offering comes out.
LOL... I suggest that you do not buy and move on to the next stinky pinkie play... I know what I own here with sfor... glut...
It's what they do. Dump shares, then reverse split. I can't remember now if this is 3rd or fourth time. If you noticed posted back in November it was likely
This is why no institution will even touch this stock again
I will buy in again after the r/s. ROSG is already undervalued, but a rs always take the pps down a little more. Sad to see this trade at this pps. Gltu zatafour.
R/S... I can't believe it...
Wow... good news today and down 11% someone is getting out at market it seems
Called that one. Another company that seems to think shareholders are nothing more than piggy banks. R/S probably coming soon as well. History repeats.
Wash, Rinse, Repeat
$ROSG Dilution. Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering https://finance.yahoo.com/news/rosetta-genomics-announces-pricing-5-203500411.html
Rosetta Genomics expects its current cash position will fund operations into May 2017
Crazy to see this stock trade at 0,56... I'm a buyer here.
On October 13, 2016, Rosetta Genomics, Ltd. (the “Company”) received a staff deficiency letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the past 30 consecutive business days, the closing bid price per share of its ordinary shares was below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As a result, the Company was notified by Nasdaq that it is not in compliance with the Bid Price Rule. Nasdaq has provided the Company with 180 calendar days, or until April 11, 2017, to regain compliance with the Bid Price Rule. This notification has no immediate effect on the Company’s listing on the Nasdaq Capital Market or on the trading of the Company’s ordinary shares.
Holding for the 2 dollar... Give it some time and load all you can under 1 Dollar. Glta
* * $ROSG Video Chart 06-21-16 * *
Link to Video - click here to watch the technical chart video
Hey old friend its being a while
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1914
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators |
http://www.rosettagenomics.com/
http://finance.yahoo.com/q/ks?s=ROSG
Rosetta Genomics, Ltd., a biotechnology company, develops microRNA-based diagnostic and therapeutic products. MicroRNAs are naturally expressed or produced using instructions encoded in DNA, and could be used in regulating protein production. The company, using its intellectual property, collaborative relationships, and microRNAs, has initiated programs to develop microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases. It primarily focuses on prostate, lung, colorectal, breast, and bladder cancers. Rosetta Genomics is also developing a diagnostic test to identify the origin of the primary tumor in metastatic cancers of unknown primary site. In addition, it is collaborating with others on the development of microRNA-based therapeutic products for the treatment of liver cancer and infectious diseases. The company has collaboration and license agreements with Asuragen, Inc.; Isis Pharmaceuticals, Inc.; Hadasit Medical Research Services and Development, Ltd.; U.S. Genomics, Inc.; The Rockefeller University; Max Planck Innovation GmbH; Johns Hopkins University; Columbia University; and Tel Hashomer Medical Research Infrastructure and Services, Ltd. Rosetta Genomics was founded in 2000 and is based in Rehovot, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |